Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

Chronic Obstructive Pulmonary Disease (COPD) and Emphysema in Emergency Medicine

  • Author: Paul Kleinschmidt, MD; Chief Editor: Barry E Brenner, MD, PhD, FACEP  more...
 
Updated: Jan 27, 2016
 

Background

Chronic obstructive pulmonary disease (COPD) is estimated to affect 32 million persons in the United States and is the fourth leading cause of death in this country. Patients typically have symptoms of both chronic bronchitis and emphysema, but the classic triad also includes asthma. Most of the time COPD is secondary to tobacco abuse, although cystic fibrosis, alpha-1 antitrypsin deficiency, bronchiectasis, and some rare forms of bullous lung diseases may be causes as well.

Patients with COPD are susceptible to many insults that can lead rapidly to an acute deterioration superimposed on chronic disease. COPD exacerbation is an important but occasionally overlooked parameter. COPD exacerbations are very common, affecting about 20% of patients with moderate-to-severe COPD (1.3 events per year in patients with 40-45% predicted FEV1). A large observational cohort study found that the rate of COPD exacerbations reflects an independent susceptibility phenotype.[1] Knowledge of this susceptibility phenotype may have implications for targeting treatment of exacerbation and prevention across all COPD severities. Quick and accurate recognition of these patients along with aggressive and prompt intervention may be the only action that prevents frank respiratory failure.

For more information, see Medscape's COPD Resource Center.

Next

Pathophysiology

Chronic obstructive pulmonary disease (COPD) is a mixture of 3 separate disease processes that together form the complete clinical and pathophysiological picture. These processes are chronic bronchitis, emphysema and, to a lesser extent, asthma. Progression of COPD is characterized by the accumulation of inflammatory mucous exudates in the lumens of small airways and the thickening of their walls. These walls become infiltrated by adaptive and innate inflammatory immune cells. Infiltration of the airways with substances such as polynuclear and mononuclear phagocytes and CD4 T cells increases with each stage of disease progression. This is also true for B cells and CD8 T cells, which organize into lymphoid follicles. This chronic inflammatory process is associated with tissue repair and remodeling that ultimately determines the pathologic type of COPD.

It appears that smoking may overcome the body's natural mechanisms for limiting this immune response. This process can continue in susceptible individuals even after smoking cessation. Even if the original noxious insults are removed, COPD is still characterized by progressive accumulation of cells of the immune system, fibrosis, and mucus hypersecretion. The molecular basis for the lung inflammation seen in COPD is still an area of great research and debate, with the potential roles of cytokines, complex autoimmune processes, and immune modulation from chronic infection all under investigation.

The defining feature of COPD is irreversible airflow limitation during forced expiration. This may be a result of a loss of elastic recoil due to lung tissue destruction or an increase in the resistance of the conducting airways. The standard measure of COPD is the measure of forced expiratory volume in 1 second (FEV1) and its ratio to forced vital capacity (FVC), FEV1/FVC.

Each case of COPD is unique in the blend of processes; however, 2 main types of the disease are recognized.

Chronic bronchitis

In this type, chronic bronchitis plays the major role. Chronic bronchitis is defined by excessive mucus production with airway obstruction and notable hyperplasia of mucus-producing glands, as depicted in the images below.

Chronic obstructive pulmonary disease (COPD). Hist Chronic obstructive pulmonary disease (COPD). Histopathology of chronic bronchitis showing hyperplasia of mucous glands and infiltration of the airway wall with inflammatory cells.
Chronic obstructive pulmonary disease (COPD). Hist Chronic obstructive pulmonary disease (COPD). Histopathology of chronic bronchitis showing hyperplasia of mucous glands and infiltration of the airway wall with inflammatory cells (high-powered view).

Damage to the endothelium impairs the mucociliary response that clears bacteria and mucus. Inflammation and secretions provide the obstructive component of chronic bronchitis. In contrast to emphysema, chronic bronchitis is associated with a relatively undamaged pulmonary capillary bed. Emphysema is present to a variable degree but usually is centrilobular rather than panlobular. The body responds by decreasing ventilation and increasing cardiac output. This V/Q mismatch results in rapid circulation in a poorly ventilated lung, leading to hypoxemia and polycythemia.

Eventually, hypercapnia and respiratory acidosis develop, leading to pulmonary artery vasoconstriction and cor pulmonale. With the ensuing hypoxemia, polycythemia, and increased CO2 retention, these patients have signs of right heart failure and are known as "blue bloaters."

Emphysema

The second major type is that in which emphysema is the primary underlying process. Emphysema is defined by destruction of airways distal to the terminal bronchiole.

Physiology of emphysema involves gradual destruction of alveolar septae and of the pulmonary capillary bed, leading to decreased ability to oxygenate blood. The body compensates with lowered cardiac output and hyperventilation. This V/Q mismatch results in relatively limited blood flow through a fairly well oxygenated lung with normal blood gases and pressures in the lung, in contrast to the situation in blue bloaters. Because of low cardiac output, however, the rest of the body suffers from tissue hypoxia and pulmonary cachexia. Eventually, these patients develop muscle wasting and weight loss and are identified as "pink puffers."

Previous
Next

Epidemiology

Frequency

United States

Two thirds of men and one fourth of women have emphysema at death. Approximately 8 million people have chronic bronchitis and 2 million have emphysema.

Mortality/Morbidity

COPD is the fourth leading cause of death in the United States, affecting 32 million adults. It is also the sixth leading cause of death worldwide.[2]

Sex

Men are more likely to have COPD than women.

Age

COPD occurs predominantly in individuals older than 40 years.

Previous
 
 
Contributor Information and Disclosures
Author

Paul Kleinschmidt, MD Consulting Staff, Department of Emergency Medicine, Womack Army Medical Center

Paul Kleinschmidt, MD is a member of the following medical societies: American Academy of Emergency Medicine

Disclosure: Received ownership interest from ScrubCast, INC for other.

Specialty Editor Board

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Paul Blackburn, DO, FACOEP, FACEP Attending Physician, Department of Emergency Medicine, Maricopa Medical Center

Paul Blackburn, DO, FACOEP, FACEP is a member of the following medical societies: American College of Emergency Physicians, Arizona Medical Association, American College of Osteopathic Emergency Physicians, American Medical Association

Disclosure: Nothing to disclose.

Chief Editor

Barry E Brenner, MD, PhD, FACEP Professor of Emergency Medicine, Professor of Internal Medicine, Program Director for Emergency Medicine, Case Medical Center, University Hospitals, Case Western Reserve University School of Medicine

Barry E Brenner, MD, PhD, FACEP is a member of the following medical societies: Alpha Omega Alpha, American Heart Association, American Thoracic Society, Arkansas Medical Society, New York Academy of Medicine, New York Academy of Sciences, Society for Academic Emergency Medicine, American Academy of Emergency Medicine, American College of Chest Physicians, American College of Emergency Physicians, American College of Physicians

Disclosure: Nothing to disclose.

References
  1. Hurst JR, Vestbo J, Anzueto A, Locantore N, Müllerova H, Tal-Singer R, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med. 2010 Sep 16. 363(12):1128-38. [Medline].

  2. Siddiqi A, Sethi S. Optimizing antibiotic selection in treating COPD exacerbations. Int J Chron Obstruct Pulmon Dis. 2008. 3(1):31-44. [Medline]. [Full Text].

  3. [Guideline] Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Bethesda (MD): Global Initiative for Chronic Obstructive Lung Disease (GOLD). 2008. [Full Text].

  4. Austin MA, Wills KE, Blizzard L, Walters EH, Wood-Baker R. Effect of high flow oxygen on mortality in chronic obstructive pulmonary disease patients in prehospital setting: randomised controlled trial. BMJ. 2010 Oct 18. 341:c5462. [Medline]. [Full Text].

  5. Pierson DJ. Indications for mechanical ventilation in adults with acute respiratory failure. Respir Care. 2002 Mar. 47(3):249-62; discussion 262-5. [Medline].

  6. Hanania NA, Donohue JF. Pharmacologic interventions in chronic obstructive pulmonary disease: bronchodilators. Proc Am Thorac Soc. 2007 Oct 1. 4(7):526-34. [Medline].

  7. Barr RG, Rowe BH, Camargo CA Jr. Methyl-xanthines for exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2001. (1):CD002168. [Medline].

  8. Puhan MA, Vollenweider D, Latshang T, Steurer J, Steurer-Stey C. Exacerbations of chronic obstructive pulmonary disease: when are antibiotics indicated? A systematic review. Respir Res. 2007. 8:30. [Medline].

  9. Rothberg MB, Pekow PS, Lahti M, Brody O, Skiest DJ, Lindenauer PK. Antibiotic therapy and treatment failure in patients hospitalized for acute exacerbations of chronic obstructive pulmonary disease. JAMA. 2010 May 26. 303(20):2035-42. [Medline].

  10. Daniels JM, Snijders D, de Graaff CS, Vlaspolder F, Jansen HM, Boersma WG. Antibiotics in addition to systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2010 Jan 15. 181(2):150-7. [Medline].

  11. Balter M, Weiss K. Treating acute exacerbations of chronic bronchitis and community-acquired pneumonia: how effective are respiratory fluoroquinolones?. Can Fam Physician. 2006 Oct. 52(10):1236-42. [Medline].

  12. [Guideline] Balter MS, La Forge J, Low DE, Mandell L, Grossman RF. Canadian guidelines for the management of acute exacerbations of chronic bronchitis. Can Respir J. 2003 Jul-Aug. 10 Suppl B:3B-32B. [Medline].

  13. Aaron SD, Vandemheen KL, Hebert P, Dales R, Stiell IG, Ahuja J, et al. Outpatient oral prednisone after emergency treatment of chronic obstructive pulmonary disease. N Engl J Med. 2003 Jun 26. 348(26):2618-25. [Medline].

  14. Alter HJ, Koepsell TD, Hilty WM. Intravenous magnesium as an adjuvant in acute bronchospasm: a meta-analysis. Ann Emerg Med. 2000 Sep. 36(3):191-7. [Medline].

  15. Baigorri F, Joseph D, Artigas A, Blanch L. Inhaled nitric oxide does not improve cardiac or pulmonary function in patients with an exacerbation of chronic obstructive pulmonary disease. Crit Care Med. 1999 Oct. 27(10):2153-8. [Medline].

  16. Curtis JL, Freeman CM, Hogg JC. The immunopathogenesis of chronic obstructive pulmonary disease: insights from recent research. Proc Am Thorac Soc. 2007 Oct 1. 4(7):512-21. [Medline].

  17. Cydulka RK, Emerman CL. Effects of combined treatment with glycopyrrolate and albuterol in acute exacerbation of chronic obstructive pulmonary disease. Ann Emerg Med. 1995 Apr. 25(4):470-3. [Medline].

  18. Dailey RH. Chronic obstructive pulmonary disease. Rosen P, et al, eds. Emergency Medicine Concepts and Clinical Practice. 3rd ed. Mosby-Year Book Inc; 1992. 1093-1111.

  19. de Palo VA. Pulmonary disease: pneumonia, chronic obstructive pulmonary disease, asthma, and thromboembolic disease. J Am Podiatr Med Assoc. 2004 Mar-Apr. 94(2):157-67. [Medline].

  20. Dewan NA, Daniels A, Zieman G, Kramer T. The National Outcomes Management Project: a benchmarking collaborative. J Behav Health Serv Res. 2000 Nov. 27(4):431-6. [Medline].

  21. Faulkner MA, Hilleman DE. Pharmacologic treatment of chronic obstructive pulmonary disease: past, present, and future. Pharmacotherapy. 2003 Oct. 23(10):1300-15. [Medline].

  22. Ferguson GT, Cherniack RM. Management of chronic obstructive pulmonary disease. N Engl J Med. 1993 Apr 8. 328(14):1017-22. [Medline].

  23. FitzGerald JM, Shragge D, Haddon J, Jennings B, Lee J, Bai T, et al. A randomized, controlled trial of high dose, inhaled budesonide versus oral prednisone in patients discharged from the emergency department following an acute asthma exacerbation. Can Respir J. 2000 Jan-Feb. 7(1):61-7. [Medline].

  24. Fromm RE Jr, Varon J. Acute exacerbations of obstructive lung disease. What to do when immediate care is crucial. Postgrad Med. 1994 Jun. 95(8):101-6. [Medline].

  25. Greenfield RH. Pulmonary disease in the elderly. Lecture presented at the ACEP Scientific Assembly. 1994.

  26. Hirschmann JV. Do bacteria cause exacerbations of COPD?. Chest. 2000 Jul. 118(1):193-203. [Medline].

  27. Hirshberg AJ, Dupper RL. Use of doxapram hydrochloride injection as an alternative to intubation to treat chronic obstructive pulmonary disease patients with hypercapnia. Ann Emerg Med. 1994 Oct. 24(4):701-3. [Medline].

  28. Ingram RH. Harrison's Principles of Internal Medicine. Fauci AS, et al, eds. Chronic bronchitis, emphysema, and airway obstruction. McGraw-Hill Companies: 1991. 1074-1082.

  29. Jaber S, Fodil R, Carlucci A, Boussarsar M, Pigeot J, Lemaire F, et al. Noninvasive ventilation with helium-oxygen in acute exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2000 Apr. 161(4 Pt 1):1191-200. [Medline].

  30. Kino RJ. The difficult COPD patient: Alternative therapy regimens. Lecture presented at the ACEP Scientific Assembly. 1996.

  31. Korosec M, Novak RD, Myers E, Skowronski M, McFadden ER Jr. Salmeterol does not compromise the bronchodilator response to albuterol during acute episodes of asthma. Am J Med. 1999 Sep. 107(3):209-13. [Medline].

  32. Lieberman D, Lieberman D, Ben-Yaakov M, Lazarovich Z, Hoffman S, Ohana B, et al. Infectious etiologies in acute exacerbation of COPD. Diagn Microbiol Infect Dis. 2001 Jul. 40(3):95-102. [Medline].

  33. Maltais F, Ostinelli J, Bourbeau J, Tonnel AB, Jacquemet N, Haddon J, et al. Comparison of nebulized budesonide and oral prednisolone with placebo in the treatment of acute exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial. Am J Respir Crit Care Med. 2002 Mar 1. 165(5):698-703. [Medline].

  34. Peng CC, Aspinall SL, Good CB, Atwood CW Jr, Chang CC. Equal effectiveness of older traditional antibiotics and newer broad-spectrum antibiotics in treating patients with acute exacerbations of chronic bronchitis. South Med J. 2003 Oct. 96(10):986-91. [Medline].

  35. Saint S, Bent S, Vittinghoff E, Grady D. Antibiotics in chronic obstructive pulmonary disease exacerbations. A meta-analysis. JAMA. 1995 Mar 22-29. 273(12):957-60. [Medline].

  36. Schmidt GA, Hall JB. Acute or chronic respiratory failure. Assessment and management of patients with COPD in the emergency setting. JAMA. 1989 Jun 16. 261(23):3444-53. [Medline].

  37. Sclar DA, Legg RF, Skaer TL, Robison LM, Nemic NL. Ipratropium bromide in the management of chronic obstructive pulmonary disease: effect on health service expenditures. Clin Ther. 1994 May-Jun. 16(3):595-601; discussion 594. [Medline].

  38. Siedman JC. Chronic obstructive pulmonary disease. Tintinalli J, et al, eds. Emergency Medicine: A Comprehensive Study Guide. McGraw-Hill Co; 1992. 298-302.

  39. Skorodin MS. Pharmacotherapy for asthma and chronic obstructive pulmonary disease. Current thinking, practices, and controversies. Arch Intern Med. 1993 Apr 12. 153(7):814-28. [Medline].

  40. Skorodin MS, Tenholder MF, Yetter B, Owen KA, Waller RF, Khandelwahl S, et al. Magnesium sulfate in exacerbations of chronic obstructive pulmonary disease. Arch Intern Med. 1995 Mar 13. 155(5):496-500. [Medline].

  41. Sohy C, Pilette C, Niederman MS, Sibille Y. Acute exacerbation of chronic obstructive pulmonary disease and antibiotics: what studies are still needed?. Eur Respir J. 2002 May. 19(5):966-75. [Medline].

  42. Stewart AG, Waterhouse JC, Billings CG, Baylis P, Howard P. Effects of angiotensin converting enzyme inhibition on sodium excretion in patients with hypoxaemic chronic obstructive pulmonary disease. Thorax. 1994 Oct. 49(10):995-8. [Medline].

  43. US Department of Health and Human Services, National Institutes of Health, Third Expert Panel on the Diagnosis and Management of Asthma. National Heart, Lung and Blood Institute National Asthma Education and Prevention Program. US Department of Health and Human Services. August 28, 2007.

  44. Varkey B. Obstructive, occupational, and environmental diseases. Curr Opin Pulm Med. 2004 Mar. 10(2):97. [Medline].

  45. [Guideline] Whittle A. COPD guidelines. Thorax. 1999 Apr. 54(4):375-6. [Medline].

  46. Zehner WJ Jr, Scott JM, Iannolo PM, Ungaro A, Terndrup TE. Terbutaline vs albuterol for out-of-hospital respiratory distress: randomized, double-blind trial. Acad Emerg Med. 1995 Aug. 2(8):686-91. [Medline].

  47. Chapman KR, Rennard SI, Dogra A, Owen R, Lassen C, Kramer B. Long-term Safety and Efficacy of Indacaterol, a Long-Acting {beta}2-Agonist, in Subjects With COPD: A Randomized, Placebo-Controlled Study. Chest. 2011 Jul. 140(1):68-75. [Medline].

 
Previous
Next
 
Chronic obstructive pulmonary disease (COPD). Histopathology of chronic bronchitis showing hyperplasia of mucous glands and infiltration of the airway wall with inflammatory cells.
Chronic obstructive pulmonary disease (COPD). Histopathology of chronic bronchitis showing hyperplasia of mucous glands and infiltration of the airway wall with inflammatory cells (high-powered view).
Posteroanterior (PA) and lateral chest radiograph in a patient with severe chronic obstructive pulmonary disease (COPD). Hyperinflation, depressed diaphragms, increased retrosternal space, and hypovascularity of lung parenchyma is demonstrated.
Chronic obstructive pulmonary disease (COPD). A lung with emphysema shows increased anteroposterior (AP) diameter, increased retrosternal airspace, and flattened diaphragms on lateral chest radiograph.
Chronic obstructive pulmonary disease (COPD). A lung with emphysema shows increased anteroposterior (AP) diameter, increased retrosternal airspace, and flattened diaphragms on posteroanterior chest radiograph.
Subcutaneous emphysema and pneumothorax.
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.